Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control study

CM. Walsh, J. Murray, I. Laponogov, A. Parker, JK. Ellis, V. Converso, E. Austin, PR. Boshier, C. Czajkowski, D. Spalding, A. Al-Mukhtar, AE. Frampton, KJ. Roberts, S. Pandanaboyana, C. Halloran, E. Costello, H. Kocher, V. Mitra, Z. Hamady, B....

. 2025 ; 15 (8) : e094505. [pub] 20250827

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, protokol klinické studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25021935

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) continues to have extremely poor patient outcomes, unlike other cancer types which have seen significant improvements in their treatments and survival. A major contributing factor is that PDAC is often detected at an advanced, incurable stage. In the UK, nearly half of patients have stage 4 disease at the time of diagnosis, which has a profound effect on treatment options and, ultimately, survival. To address the challenge of early detection of PDAC, this study aims to develop and validate a clinical prediction model based on a non-invasive breath test. The proposed breath test aims to assist general practitioners in the triaging of patients who present with symptoms that do not meet current criteria for urgent suspected PDAC pathway referral. METHODS AND ANALYSIS: The Volatile organic compound Assessment in Pancreatic ductal adenOcaRcinoma (VAPOR 1) study is a prospective, multicentre, case-control study that aims to recruit 771 participants from England, Wales and Scotland. These include adult participants, aged ≥18 years, in three cohorts: pancreatic ductal adenocarcinoma; benign pancreatic controls (chronic pancreatitis or new-onset diabetes); healthy controls with a normal pancreas on imaging. A one-off breath sample will be obtained from participants who have fasted for at least 6 hours, and participant demographics and clinical data will be recorded. Breath samples will be analysed using gas chromatography-mass spectrometry to identify the volatile organic compounds (VOCs) present. Relationships between VOCs of interest and the presence of PDAC will be explored, and a clinical prediction model will be developed using statistical and machine learning methods and internally validated. ETHICS AND DISSEMINATION: The VAPOR 1 study has received approval from the South East Scotland Research Ethics Committee 02, and from the Health Research Authority and Health and Care Research Wales (REC 22/SS/0061). Results of this study will be published in open-access peer-reviewed journals, and disseminated through pancreatic cancer conference presentations. In addition, lay summaries shared on our website, social media platforms and through our charitable funder, Pancreatic Cancer UK, will enable engagement with patients and the wider public. TRIAL REGISTRATION NUMBER: NCT05727020.

Barts Health NHS Trust London UK

Buckinghamshire Healthcare NHS Trust Amersham UK

Department of Chemistry of Ions in Gaseous Phase J Heyrovsky Institute of Physical Chemistry Czech Academy of Sciences Praha Czech Republic

Department of Medical Statistics Faculty of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London UK

Department of Molecular and Clinical Cancer Medicine University of Liverpool Liverpool UK

Department of Surgery and Cancer Faculty of Medicine Imperial College London London UK

Dorset County Hospital NHS Foundation Trust Dorchester UK

Imperial College Healthcare NHS Trust London UK

Imperial College London London UK

Leeds Teaching Hospitals NHS Trust Leeds UK

Liverpool University Hospitals NHS Foundation Trust Liverpool UK

Manchester University NHS Foundation Trust Manchester UK

Milton Keynes University Hospital NHS Foundation Trust Milton Keynes UK

Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle Upon Tyne UK

North Tees and Hartlepool NHS Foundation Trust Hartlepool UK

Patient and Public Involvement Representative Pancreatic Cancer UK London UK

Royal Free Hospital Campus University College London London UK

Royal Surrey NHS Foundation Trust Guildford UK

Section of Oncology University of Surrey Guildford UK

Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK

Swansea Bay University Health Board Port Talbot UK

University Hospital Southampton NHS Foundation Trust Southampton UK

University Hospitals Birmingham NHS Foundation Trust Birmingham UK

University Hospitals Plymouth NHS Trust Plymouth UK

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25021935
003      
CZ-PrNML
005      
20251023075949.0
007      
ta
008      
251014s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2024-094505 $2 doi
035    __
$a (PubMed)40866056
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Walsh, Caoimhe M $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK $1 https://orcid.org/0000000222579063
245    10
$a Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control study / $c CM. Walsh, J. Murray, I. Laponogov, A. Parker, JK. Ellis, V. Converso, E. Austin, PR. Boshier, C. Czajkowski, D. Spalding, A. Al-Mukhtar, AE. Frampton, KJ. Roberts, S. Pandanaboyana, C. Halloran, E. Costello, H. Kocher, V. Mitra, Z. Hamady, B. Al-Sarireh, S. Pathak, WK. Mitchell, AK. Siriwardena, C. Westlake, SP. Pereira, I. Spiliotis, S. Biswas, . Vapor Collaborators, P. Španěl, K. Veselkov, LD. Sharples, GB. Hanna, VAPOR Collaborators
520    9_
$a INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) continues to have extremely poor patient outcomes, unlike other cancer types which have seen significant improvements in their treatments and survival. A major contributing factor is that PDAC is often detected at an advanced, incurable stage. In the UK, nearly half of patients have stage 4 disease at the time of diagnosis, which has a profound effect on treatment options and, ultimately, survival. To address the challenge of early detection of PDAC, this study aims to develop and validate a clinical prediction model based on a non-invasive breath test. The proposed breath test aims to assist general practitioners in the triaging of patients who present with symptoms that do not meet current criteria for urgent suspected PDAC pathway referral. METHODS AND ANALYSIS: The Volatile organic compound Assessment in Pancreatic ductal adenOcaRcinoma (VAPOR 1) study is a prospective, multicentre, case-control study that aims to recruit 771 participants from England, Wales and Scotland. These include adult participants, aged ≥18 years, in three cohorts: pancreatic ductal adenocarcinoma; benign pancreatic controls (chronic pancreatitis or new-onset diabetes); healthy controls with a normal pancreas on imaging. A one-off breath sample will be obtained from participants who have fasted for at least 6 hours, and participant demographics and clinical data will be recorded. Breath samples will be analysed using gas chromatography-mass spectrometry to identify the volatile organic compounds (VOCs) present. Relationships between VOCs of interest and the presence of PDAC will be explored, and a clinical prediction model will be developed using statistical and machine learning methods and internally validated. ETHICS AND DISSEMINATION: The VAPOR 1 study has received approval from the South East Scotland Research Ethics Committee 02, and from the Health Research Authority and Health and Care Research Wales (REC 22/SS/0061). Results of this study will be published in open-access peer-reviewed journals, and disseminated through pancreatic cancer conference presentations. In addition, lay summaries shared on our website, social media platforms and through our charitable funder, Pancreatic Cancer UK, will enable engagement with patients and the wider public. TRIAL REGISTRATION NUMBER: NCT05727020.
650    _2
$a lidé $7 D006801
650    12
$a duktální karcinom slinivky břišní $x diagnóza $7 D021441
650    12
$a nádory slinivky břišní $x diagnóza $7 D010190
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a prospektivní studie $7 D011446
650    12
$a těkavé organické sloučeniny $x analýza $7 D055549
650    _2
$a dechové testy $x metody $7 D001944
650    _2
$a multicentrické studie jako téma $7 D015337
650    12
$a časná detekce nádoru $x metody $7 D055088
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    _2
$a mužské pohlaví $7 D008297
651    _2
$a Spojené království $7 D006113
655    _2
$a časopisecké články $7 D016428
655    _2
$a protokol klinické studie $7 D000078325
700    1_
$a Murray, James $u Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK $1 https://orcid.org/0000000264944815
700    1_
$a Laponogov, Ivan $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
700    1_
$a Parker, Aaron $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
700    1_
$a Ellis, James K $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK $1 https://orcid.org/0000000175534486
700    1_
$a Converso, Valerio $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
700    1_
$a Austin, Emma $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
700    1_
$a Boshier, Piers R $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
700    1_
$a Czajkowski, Charles $u Patient and Public Involvement Representative, Pancreatic Cancer UK, London, UK
700    1_
$a Spalding, Duncan $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK $u Imperial College Healthcare NHS Trust, London, UK
700    1_
$a Al-Mukhtar, Ahmed $u Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
700    1_
$a Frampton, Adam E $u Royal Surrey NHS Foundation Trust, Guildford, UK $u Section of Oncology, University of Surrey, Guildford, UK
700    1_
$a Roberts, Keith J $u University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
700    1_
$a Pandanaboyana, Sanjay $u Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
700    1_
$a Halloran, Chris $u Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK $u Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK $1 https://orcid.org/0000000254714178
700    1_
$a Costello, Eithne $u Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK $1 https://orcid.org/0000000201048992
700    1_
$a Kocher, Hemant $u Barts Health NHS Trust, London, UK
700    1_
$a Mitra, Vikramjit $u North Tees and Hartlepool NHS Foundation Trust, Hartlepool, UK
700    1_
$a Hamady, Zaed $u University Hospital Southampton NHS Foundation Trust, Southampton, UK
700    1_
$a Al-Sarireh, Bilal $u Swansea Bay University Health Board, Port Talbot, UK
700    1_
$a Pathak, Samir $u Leeds Teaching Hospitals NHS Trust, Leeds, UK
700    1_
$a Mitchell, William Kyle $u Dorset County Hospital NHS Foundation Trust, Dorchester, UK
700    1_
$a Siriwardena, Ajith Kumar $u Manchester University NHS Foundation Trust, Manchester, UK
700    1_
$a Westlake, Claire $u University Hospitals Plymouth NHS Trust, Plymouth, UK
700    1_
$a Pereira, Stephen P $u Royal Free Hospital Campus, University College London, London, UK
700    1_
$a Spiliotis, Ioannis $u Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK
700    1_
$a Biswas, Sujata $u Buckinghamshire Healthcare NHS Trust, Amersham, UK
700    1_
$a Vapor Collaborators, $u Imperial College London, London, UK
700    1_
$a Španěl, Patrik $u Department of Chemistry of Ions in Gaseous Phase, J Heyrovsky Institute of Physical Chemistry Czech Academy of Sciences, Praha, Czech Republic
700    1_
$a Veselkov, Kirill $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
700    1_
$a Sharples, Linda D $u Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK $1 https://orcid.org/000000030894966X
700    1_
$a Hanna, George B $u Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK g.hanna@imperial.ac.uk
710    2_
$a VAPOR Collaborators
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 15, č. 8 (2025), s. e094505
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40866056 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20251014 $b ABA008
991    __
$a 20251023075955 $b ABA008
999    __
$a ok $b bmc $g 2417017 $s 1260098
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 15 $c 8 $d e094505 $e 20250827 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20251014

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace